Sage Therapeutics, Inc. (SAGE:NSD) has garnered an average rating of “Hold” from 15 brokerages currently covering the stock. Among the analysts, 11 gave the stock a hold rating, while three rated it as a buy. The average price target for SAGE stock over the next 12 months, as issued by analysts in the past year, is $49.20.
SAGE Stock-Analyst Ratings:
In recent months, SAGE has been the subject of various research reports. BMO Capital Markets reduced the company’s price target from $43.00 to $40.00 and gave it a “market perform” rating in November 2022. Citigroup, on the other hand, raised the company’s price target from $40.00 to $46.00 and rated SAGE stock as “neutral” in February 2022.
Guggenheim lowered its rating from “buy” to “neutral” in January 2022. Mizuho raised its target price from $37.00 to $45.00 and gave the stock a “neutral” rating in February 2022. Needham & Company LLC reaffirmed a “buy” rating with a $70.00 target price in February 2022.
SAGE Stock Price Analysis:
SAGE opened at $44.42 on Thursday, with a 50-day moving average of $42.89 and a 200-day moving average of $40.21. The company has a market capitalization of $2.65 billion, a PE ratio of -4.95, and a beta of 1.15. The stock’s 52-week range is $27.36 to $49.56.
Quarterly Earnings Review:
For the quarter ended February 16, 2022, Sage Therapeutics reported a net loss of $2.47 per share, missing the consensus estimate by $0.10. The company had revenue of $2.87 million for the quarter, up 74.7% from the same period last year.
However, SAGE had a negative net margin of 6,930.97% and a negative return on equity of 37.03%. Analysts project that SAGE will post a loss of $8.2 per share for the current fiscal year.
In terms of insider trading, Director Jeffrey M. Jonas sold 11,643 shares of the company’s stock on February 10, 2022, at an average price of $44.61 per share, for a total value of $519,394.23. Following the sale, Jonas now holds 121,981 shares in SAGE, valued at $5,441,572.41. Insiders hold 4.80% of SAGE stock.
Hedge Funds & Institutional Holdings:
Institutional investors and hedge funds have bought and sold shares of SAGE recently. Baillie Gifford & Co. increased its position in SAGE stock by 3.3% during the third quarter and now owns 91,395 shares worth $3,580,000.
Primecap Management Co. CA raised its holdings by 13.1% in the second quarter and now owns 77,800 shares worth $2,513,000. E Fund Management Co. Ltd. raised its holdings by 4.1% in the third quarter and now owns 11,341 shares worth $444,000. Point72 Hong Kong Ltd raised its holdings by 13.4% in the second quarter and now owns 9,927 shares worth $321,000. TD Asset Management Inc. raised its holdings by 0.7% in the third quarter and now owns 59,355 shares worth $2,350,000.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases.
The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.